Program
SKB500
A development code. Also written as “SKB500 Powder for Injection”.
Its studies are mostly in Esophageal Squamous Cell Carcinoma · Small Cell Lung Carcinoma, led by Sichuan Kelun Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical | 33 open or running | phase 2since Nov 25, 2025 | Dec 9, 2024 | Jul 31, 2027phase 1 · NCT06736327 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 9, 2024First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06736327 · 180 planned · China
- Nov 25, 2025Phase 2 study in Small Cell Lung CarcinomaPhase 2 reachedNCT07296809 · 80 planned · China
- Jul 8, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaNCT07700667 · 120 planned · China
Ahead
- Jul 31, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT06736327
- Dec 31, 2028Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaNCT07700667
- Dec 31, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07296809
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07700667Esophageal Squamous Cell Carcinoma · China | 2 | Recruiting | Dec 31, 2028 | 120 |
| NCT07296809Small Cell Lung Carcinoma · China | 2 | Recruiting | Dec 31, 2028 | 80 |
| NCT06736327Advanced Solid Tumors · China | 1 | Recruiting | Jul 31, 2027 | 180 |
How it is read
Names in the registry
- “SKB500”, 2 entries
- “SKB500 Powder for Injection”, 1 entry
Codes read as this program: SKB500.
Conditions, from the studies’ own filings
- Esophageal Squamous Cell Carcinoma, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.